Format
Sort by
Items per page

Send to

Choose Destination

Best matches for László Vécsei:

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. Montalban X et al. N Engl J Med. (2017)

Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection. Sas K et al. Molecules. (2018)

Monoamine Oxidase B Inhibitors in Parkinson's Disease. Dezsi L et al. CNS Neurol Disord Drug Targets. (2017)

Search results

Items: 1 to 20 of 398

1.

Epidemiology of multiple sclerosis in Central Europe, update from Hungary.

Biernacki T, Sandi D, Fricska-Nagy Z, Kincses ZT, Füvesi J, Laczkó R, Kokas Z, Klivényi P, Vécsei L, Bencsik K.

Brain Behav. 2020 Mar 20:e01598. doi: 10.1002/brb3.1598. [Epub ahead of print]

2.

Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy.

Fakan B, Reisz Z, Zadori D, Vecsei L, Klivenyi P, Szalardy L.

J Neural Transm (Vienna). 2020 Mar 19. doi: 10.1007/s00702-020-02174-2. [Epub ahead of print]

PMID:
32193732
3.

'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.

Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group.

J Neurol. 2020 Mar 18. doi: 10.1007/s00415-020-09770-y. [Epub ahead of print]

PMID:
32189108
4.

A validated UHPLC-MS method for tryptophan metabolites: Application in the diagnosis of multiple sclerosis.

Tömösi F, Kecskeméti G, Cseh EK, Szabó E, Rajda C, Kormány R, Szabó Z, Vécsei L, Janáky T.

J Pharm Biomed Anal. 2020 Mar 9;185:113246. doi: 10.1016/j.jpba.2020.113246. [Epub ahead of print]

PMID:
32182446
5.

[Kynurenines and drug research].

Tóth F, Fülöp F, Szatmári I, Toldi J, Dékány I, Vécsei L.

Orv Hetil. 2020 Mar;161(12):443-451. doi: 10.1556/650.2020.31673. Hungarian.

PMID:
32172583
6.

Antidepressant-like effects of kynurenic acid in a modified forced swim test.

Tanaka M, Bohár Z, Martos D, Telegdy G, Vécsei L.

Pharmacol Rep. 2020 Apr;72(2):449-455. doi: 10.1007/s43440-020-00067-5. Epub 2020 Mar 12.

PMID:
32162182
7.

Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial.

Chabriat H, Bassetti CL, Marx U, Audoli-Inthavong ML, Sors A, Lambert E, Wattez M, Hermann DM; RESTORE BRAIN study investigators.

Lancet Neurol. 2020 Mar;19(3):226-233. doi: 10.1016/S1474-4422(20)30004-1.

PMID:
32085836
8.

Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists.

Szűcs E, Stefanucci A, Dimmito MP, Zádor F, Pieretti S, Zengin G, Vécsei L, Benyhe S, Nalli M, Mollica A.

Biomolecules. 2020 Feb 12;10(2). pii: E284. doi: 10.3390/biom10020284.

9.

[Current questions of multiple sclerosis: the secunder progressive form of the disease].

Vécsei L.

Ideggyogy Sz. 2020 Jan 30;73(1-2):7-14. doi: 10.18071/isz.73.0007. Review. Hungarian.

PMID:
32057199
10.

Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism.

Tanaka M, Bohár Z, Vécsei L.

Molecules. 2020 Jan 28;25(3). pii: E564. doi: 10.3390/molecules25030564. Review.

11.

Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson's disease.

Boros FA, Maszlag-Török R, Vécsei L, Klivényi P.

Brain Res. 2020 Mar 1;1730:146672. doi: 10.1016/j.brainres.2020.146672. Epub 2020 Jan 14.

PMID:
31953211
12.

Therapeutic Approaches for Peripheral and Central Neuropathic Pain.

Szok D, Tajti J, Nyári A, Vécsei L.

Behav Neurol. 2019 Nov 21;2019:8685954. doi: 10.1155/2019/8685954. eCollection 2019. Review.

13.

Utilization of acute vascular imaging and neurointervention for acute ischaemic stroke patients in 20 Hungarian stroke centers.

Pozsegovits K, Szabó G, Szupera Z, Nagy P, Németh L, Kondákor I, Tusa C, Berente L, Salacz P, Vécsei L, Sas K, Semjén J, Nikl J, Szapáry L, Kakuk A, Rózsa C, Horváth M, Imre P, Köves Á, Balogh I, Molnár S, Folyovich A, Al-Muhanna N, Béres-Molnár AK, Hahn K, Kristóf P, Szász AS, Szűcs A, Bereczki D.

Ideggyogy Sz. 2019 Nov 30;72(11-12):407-412. doi: 10.18071/isz.72.0407.

PMID:
31834684
14.

The effect of psychiatric comorbidities and stress-coping strategies on perceived quality of life in migraine.

Petrovics-Balog A, Majláth Z, Melinda L, Holczer A, Must A, Tajti J, Vécsei L.

Ideggyogy Sz. 2019 Nov 30;72(11-12):397-404. doi: 10.18071/isz.72.0397.

PMID:
31834683
15.

Neuroprotection in Parkinson's disease: facts and hopes.

Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L.

J Neural Transm (Vienna). 2019 Dec 11. doi: 10.1007/s00702-019-02115-8. [Epub ahead of print] Review.

PMID:
31828513
16.

Temporal instability of salience network activity in migraine with aura.

Veréb D, Szabó N, Tuka B, Tajti J, Király A, Faragó P, Kocsis K, Tóth E, Bozsik B, Kincses B, Vécsei L, Kincses ZT.

Pain. 2020 Apr;161(4):856-864. doi: 10.1097/j.pain.0000000000001770.

PMID:
31815918
17.

Immunomodulatory Effects of Genetic Alterations Affecting the Kynurenine Pathway.

Boros FA, Vécsei L.

Front Immunol. 2019 Nov 6;10:2570. doi: 10.3389/fimmu.2019.02570. eCollection 2019. Review.

18.

Contributing factors to health-related quality of life in multiple sclerosis.

Biernacki T, Sandi D, Kincses ZT, Füvesi J, Rózsa C, Mátyás K, Vécsei L, Bencsik K.

Brain Behav. 2019 Dec;9(12):e01466. doi: 10.1002/brb3.1466. Epub 2019 Nov 11.

19.

Opicapone for the treatment of Parkinson's disease: an update.

Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L.

Expert Opin Pharmacother. 2019 Dec;20(18):2201-2207. doi: 10.1080/14656566.2019.1681971. Epub 2019 Oct 31. Review.

PMID:
31670988
20.

Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose?

Szpisjak L, Salamon A, Zadori D, Klivenyi P, Vecsei L.

Expert Opin Pharmacother. 2020 Jan;21(1):1-4. doi: 10.1080/14656566.2019.1685980. Epub 2019 Oct 30. No abstract available.

PMID:
31663787

Supplemental Content

Loading ...
Support Center